目的评价CT引导下~(125)I放射性粒子植入术联合FOLFIRI方案化疗二线治疗直肠癌术后辅助放疗后局部复发的疗效和安全性。方法 34例既往有局部放疗史的直肠癌术后局部复发患者分为2组,对照组仅予FOLFIRI方案化疗,研究组予~(125)I放射性粒子植入联合FOLFIRI方案化疗。术后每2个月参照RECIST标准评价近期疗效,采用寿命表法计算1、2、3 a生存率,采用log rank法比较亚组生存差异并绘制生存曲线。结果对照组有效率为25.0%,研究组为100.0%(P〈0.001)。中位局部控制时间对照组为4个月,研究组为12个月(P〈0.001);2组总生存时间分别为19、36个月(P=0.0168)。结论 CT引导下~(125)I放射性粒子植入术联合FOLFIRI方案化疗可作为直肠癌术后辅助放疗后局部复发的补救治疗。
Objective To evaluate the efficacy and safety of CT guided~(125)I-seed implantation plus FOLFIRI regimen chemotherapyas second-line treatment for locally recurrent rectal cancerwith adjuvant radiotherapy. Methods Thirty-four patients with locally recurrent rectal cancer were divided intotwo groups. The patients in the control group received the FOLFIRI regimen alone,and the patients in the study group received the~(125)I-seed implantation plus FOLFIRI regimen. The short-term effect was evaluated by using RECIST criteria every two months after treatment.The 1-,2-and 3-year survival rates were estimated by using the life table method. Log rank method was used to test the difference of survival in subgroup. Results The overall response rate in the control group was 25. 0%,and was100. 0% in the study group( P〈0. 001). The local control time in the control group was 4 months and was 12 months in the study group; the overall survival time in the control group was 19 months,and was 36 months in the study group( P 0. 001). Conclusion CT-guided125 I seed implantation plus FOLFIRI regimen chemotherapy can be a salvage therapy for locally recurrent rectal cancer with adjuvant radiotherapy.